PENETRATION OF CEFPODOXIME PROXETIL IN LUNG PARENCHYMA AND EPITHELIAL LINING FLUID OF NONINFECTED PATIENTS

被引:16
作者
MULLERSERIEYS, C
BANCAL, C
DOMBRET, MC
SOLER, P
MURCIANO, G
AUBIER, M
BERGOGNEBEREZIN, E
机构
[1] BICHAT CLAUDE BERNARD UNIV HOSP,DEPT MICROBIOL,46 RUE HENRI HUCHARD,F-75877 PARIS 18,FRANCE
[2] BICHAT CLAUDE BERNARD UNIV HOSP,DEPT PNEUMOL,F-75877 PARIS 18,FRANCE
[3] BICHAT CLAUDE BERNARD UNIV HOSP,INSERM,U226,F-75877 PARIS 18,FRANCE
[4] BICHAT CLAUDE BERNARD UNIV HOSP,INSERM,U482,F-75877 PARIS 18,FRANCE
[5] BICHAT CLAUDE BERNARD UNIV HOSP,THORAC & CARDIAC SURG UNIT,F-75877 PARIS 18,FRANCE
关键词
D O I
10.1128/AAC.36.10.2099
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The pulmonary disposition of cefpodoxime was studied in 12 patients with pulmonary opacities after a single oral dose of 260 mg of cefpodoxime-proxetil, which is equivalent to 200 mg of cefpodoxime. Blood and lung tissue samples were collected during surgery, and bronchoalveolar lavage was carried out 3 h (group A) or 6 h (group B) after drug administration. Urea was used as an endogenous marker for measurement of the volume of epithelial lining fluid (ELF). Concentrations were measured by using a microbiological assay. The mean concentrations of cefpodoxime in plasma, ELF, and lung tissue were, respectively, 1.85 +/- 0.82 mg/liter, 0.22 +/- 0.13 mg/liter, and 0.89 +/- 0.80 mg/kg of body weight in group A and 1.40 +/- 1.25 mg/liter, 0.12 +/- 0.14 mg/liter, and 0.84 +/- 0.61 mg/kg in group B. Concentrations in lung parenchyma 6 h after dosing were at least equal to or above the MICs for 90% of the strains of most organisms commonly found in respiratory tract infections, whereas data for ELF suggest levels of drug insufficient to inhibit bacteria.
引用
收藏
页码:2099 / 2103
页数:5
相关论文
共 18 条
[1]  
BERGOGNEBEREZIN E, 1988, RESPIRATORY INFECTIO, P608
[2]   PULMONARY DISPOSITION OF TOBRAMYCIN [J].
BRAUDE, AC ;
HORNSTEIN, A ;
KLEIN, M ;
VAS, S ;
REBUCK, AS .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1983, 127 (05) :563-565
[3]   PULMONARY DISPOSITION OF ROXITHROMYCIN (RU-28965), A NEW MACROLIDE ANTIBIOTIC [J].
CHASTRE, J ;
BRUN, P ;
FOURTILLAN, JB ;
SOLER, P ;
BASSET, G ;
MANUEL, C ;
TROUILLET, JL ;
GIBERT, C .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (09) :1312-1316
[4]   CONCENTRATIONS OF CEFPODOXIME IN PLASMA AND LUNG-TISSUE AFTER A SINGLE ORAL DOSE OF CEFPODOXIME PROXETIL [J].
COURAUD, L ;
ANDREWS, JM ;
LECOEUR, H ;
SULTAN, E ;
LENFANT, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1990, 26 :35-40
[5]  
HAND WL, 1984, AM REV RESPIR DIS, V129, P933
[6]  
HUNNINGHAKE GW, 1979, AM J PATHOL, V97, P149
[7]   ANTIBACTERIAL ACTIVITIES OF CEFPODOXIME, CEFIXIME, AND CEFTRIAXONE [J].
KNAPP, CC ;
SIERRAMADERO, J ;
WASHINGTON, JA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (12) :1896-1898
[8]   TOBRAMYCIN CONCENTRATIONS IN HUMAN LUNG-TISSUE [J].
KROENING, U ;
LIEBIG, S ;
WUNDSCHOCK, M .
INFECTION, 1978, 6 (05) :231-235
[9]   PHARMACOKINETICS AND INFLAMMATORY FLUID PENETRATION OF CEFPODOXIME PROXETIL IN VOLUNTEERS [J].
ONEILL, P ;
NYE, K ;
DOUCE, G ;
ANDREWS, J ;
WISE, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (02) :232-234
[10]   ESTIMATION OF VOLUME OF EPITHELIAL LINING FLUID RECOVERED BY LAVAGE USING UREA AS MARKER OF DILUTION [J].
RENNARD, SI ;
BASSET, G ;
LECOSSIER, D ;
ODONNELL, KM ;
PINKSTON, P ;
MARTIN, PG ;
CRYSTAL, RG .
JOURNAL OF APPLIED PHYSIOLOGY, 1986, 60 (02) :532-538